Jindal Supreme IPO
₹88 – ₹88 · Issue Size ₹124.88 CrIPO Overview
Business Model
- Led by qualified and experienced Promoter and supported by a professional management team and strong
- We have a dedicated experienced management team with in our company. We are guided by the experience, vision
- Directors and SMPs. For details in relation to our Promoters, Directors, KMPs and SMPs, see "Our Promoters,
- Promoter Group" and "Our Management" beginning on pages 222 and 207, respectively. In addition, continued talent
IPO Timeline
Risk Factors
Strengths & Weaknesses
Strengths
- Led by qualified and experienced Promoter and supported by a professional management team and strong
- We have a dedicated experienced management team with in our company. We are guided by the experience, vision
- Directors and SMPs. For details in relation to our Promoters, Directors, KMPs and SMPs, see "Our Promoters,
- Promoter Group" and "Our Management" beginning on pages 222 and 207, respectively. In addition, continued talent
Management & Promoters
Peer Comparison
| Company | P/E | EPS |
|---|---|---|
| Jindal Supreme IPO | — | — |
| Dated: April | 13.0x | — |
| Please read section of the Companies Act | 32.0x | — |
| Dated: April | 13.0x | — |
Pre-IPO Financials
| Period | Revenue (Cr) | PAT (Cr) | Net Worth (Cr) | Total Assets (Cr) |
|---|---|---|---|---|
| December 2025 | ₹1.09 Cr | ₹0.7 Cr | ₹12.87 Cr | ₹87.76 Cr |
| 2025 | ₹114.71 Cr | ₹4.4 Cr | — | ₹121.88 Cr |
| 2024 | — | — | ₹0.63 Cr | ₹0.04 Cr |
| 2023 | — | — | — | ₹121.93 Cr |
About
Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medica
Key Regulations and Policies", "History and Certain Corporate Matters", "Restated Financial Information", "Financial Indebtedness", "Outstanding Litigation and Material Developments", "Other Regulatory and Statutory Disclosures" and "Main Provision of the Articles of Association" beginning on pages 94, 103, 113, 115, 191, 202, 229, 298, 317, and 362 respectively, shall have the meanings ascribed to them in the relevant section. General Terms Term Description "Our Company" or "the Company" or "the issuer" or "Jindal" Jindal Supreme (India) Limited (formerly known as Jindal Supreme (India) P
| Exchange | NSE |
| Issue Type | mainboard |
| Face Value | ₹10 per share |
Documents
rupiya.io is for research and education only. IPO data is sourced from public disclosures (DRHP/RHP). Not investment advice. Validate with SEBI-regulated disclosures before acting.